Easing Policy Risks And New Therapy Launches Will Drive Shares Higher

Key Takeaways

• Biogen is positioned for long-term growth through expanding global access to key therapies, leveraging increasing disease diagnoses and improved healthcare infrastructure.
  
• Streamlined operations, diverse late-stage pipeline, and digital engagement efforts are expected to strengthen earnings and reduce future revenue volatility.
  
• Biogen faces intense competition, pricing, and policy pressures, making its future growth highly dependent on the success of a few new product launches.

Catalysts

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

• Demand for Biogen's Alzheimer's therapy LEQEMBI is poised for structural long-term growth, supported by a rapidly aging global population and accelerating rates of mild cognitive impairment diagnoses facilitated by breakthroughs in blood-based biomarkers and expanding diagnostic infrastructure. These factors position Biogen to capture a larger patient pool and drive sustained revenue expansion.
  
• Broad international rollout and expanding reimbursement for SKYCLARYS and ZURZUVAE, particularly in rare diseases and underpenetrated markets, leverages growing global healthcare spending and improvements in medical infrastructure worldwide, increasing access and boosting long-term topline growth.
  
• Enhancements in operational efficiency through ongoing "Fit for Growth" initiatives, disciplined cost management, and portfolio prioritization are expected to improve cost control, drive higher net margins over time, and support stronger earnings.
  
• Robust late-stage and diversified neurodegenerative and specialty disease pipelines-including Phase III launches in SMA, lupus, and kidney indications-capitalize on regulatory momentum to address high unmet needs, creating multiple shots on goal that reduce future revenue volatility and support long-term earnings stability.
  
• Adoption of digital health, streamlined diagnostics, and direct-to-consumer patient engagement campaigns (especially for LEQEMBI) are expected to accelerate diagnosis, increase therapy uptake, and support value-based pricing, contributing to higher revenue and improved margin capture.

Biogen Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Biogen's revenue will grow by 2.3% annually over the next 3 years.
• Analysts assume that profit margins will increase from 13.8% today to 21.3% in 3 years time.
• Analysts expect earnings to reach $2.3 billion (and earnings per share of $13.55) by about July 2029, up from $1.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $3.0 billion in earnings, and the most bearish expecting $1.8 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 18.7x on those 2029 earnings, down from 21.9x today. This future PE is greater than the current PE for the US Biotechs industry at 17.2x.
• Analysts expect the number of shares outstanding to grow by 0.7% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.47%, as per the Simply Wall St company report.

Risks

• Ongoing and accelerating competitive pressures in the ex-U.S. multiple sclerosis (MS) business, particularly for TECFIDERA in Europe due to generic and biosimilar entrants, are expected to impact revenue and market share, leading to potential further erosion of international sales and profit margins.
  
• Despite claims of pipeline advancement, Biogen's future growth remains heavily dependent on the commercial performance of a small number of new launches (e.g., LEQEMBI, SKYCLARYS, ZURZUVAE); any clinical, regulatory, or commercial setbacks for these assets could threaten revenue stability and long-term earnings.
  
• Industry-wide shifts toward biosimilars and generics, as well as government and payer policy pressures around high-cost specialty therapies (including mounting reimbursement challenges and discount dynamics, especially in international markets), are likely to compress gross margins and restrain topline growth for Biogen's core branded portfolio.
  
• The Alzheimer's and lupus markets are becoming increasingly competitive with the entry of new therapies and alternative modalities; Biogen may face headwinds related to differentiation, efficacy, and market adoption, which could dampen the ramp-up of key pipeline assets and future revenue streams.
  
• The sustainability of cost controls and margin expansion (via Fit for Growth and restructuring initiatives) is uncertain, especially as Biogen plans increased R&D investments and faces higher interest costs from additional debt-potentially pressuring net earnings if topline growth does not keep pace.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $227.59 for Biogen based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $300.0, and the most bearish reporting a price target of just $157.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $10.6 billion, earnings will come to $2.3 billion, and it would be trading on a PE ratio of 18.7x, assuming you use a discount rate of 7.5%.
• Given the current share price of $203.16, the analyst price target of $227.59 is 10.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.